phrykt

Protalix BioTherapeutics, Inc. (PLX): who owns it and who trades it

As of Nov 16, 2026, PLX insiders reported 1 open-market sale worth $314 and 1 purchase worth $101K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Amos Bar-Shalev (Director), with $314. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Protalix BioTherapeutics

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PLX

102 funds and institutions reported PLX shares worth $34.1M at the end of Q2 2026, about 18% of the company. The largest holder is BlackRock, Inc. with 5.0%.

Funds and institutions (13F) 18%Everyone else 82%

10 largest owners, by share of the company

BlackRock, Inc.5.0%
Renaissance Technologies LLC1.4%
State Street Corp1.2%
Geode Capital Management, LLC1.2%
Northern Trust Corp1.1%
Vanguard Portfolio Management LLC0.6%
Stratos Wealth Partners, LTD.0.6%
Dimensional Fund Advisors LP0.6%
Goldman Sachs Group Inc0.6%
Marshall Wace, LLP0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.4.05M5.02%$9.4M+12%
Renaissance Technologies LLC1.10M1.36%$2.6M-11%
State Street Corp983,5821.22%$2.3M+1%
Geode Capital Management, LLC979,9951.22%$2.3M+13%
Northern Trust Corp922,3401.14%$2.1M+4%
Vanguard Portfolio Management LLC510,6390.63%$1.2M+18%
Stratos Wealth Partners, LTD.500,0000.62%$1.2MNo change
Dimensional Fund Advisors LP493,4240.61%$1.1M+66%
Goldman Sachs Group Inc475,9220.59%$1.1M+89%
Marshall Wace, LLP452,7570.56%$1.1MNew
Citadel Advisors LLC334,2270.41%$779KNew
Strs Ohio296,1000.37%$690KNew
Bank of New York Mellon Corp232,9920.29%$543K+6%
Main Street Financial Solutions, LLC214,1000.27%$499KNew
Bridgeway Capital Management, LLC189,1000.23%$441KNo change
Hillsdale Investment Management Inc.185,7110.23%$433KNew
Charles Schwab Investment Management Inc180,3810.22%$420K+13%
Sixth Street Partners Management Company, L.P.180,3810.22%$420KNew
Millennium Management LLC171,5350.21%$400KNew
AQR Capital Management LLC167,8260.21%$391K+450%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PLX insiders reported $101K of open-market purchases and $314 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$101K
1 trades, 1 people
Sales, 12 months
$314
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 19, 2025
Filed Dec 23, 2025

Purchases and sales by month

$101K$101KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 19, 2025Dror BashanCEOPurchase56,000$1.81$101KForm 4
Nov 18, 2025Amos Bar-ShalevDirectorSale168$1.87$314Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Dror BashanPRESIDENT AND CEO, Director$101K–Dec 19, 2025
Amos Bar-ShalevDirector–$314Nov 18, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PLX short interest

Low short interest. 4.3% of PLX shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.48M PLX shares were sold short, 4.3% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 563,101 shares, buying them all back would take about 6.2 trading days (days to cover).

Shares short, % of all shares

4.32%May 15Oct 305.44%

Days to cover

6.2May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.48M4.32%-1%563,1016.2
Oct 15, 20263.51M4.35%+15%1.07M3.3
Sep 30, 20263.04M3.77%+6%709,0694.3
Sep 15, 20262.88M3.57%-9%754,1463.8
Aug 31, 20263.17M3.93%-11%666,4064.8
Aug 14, 20263.58M4.44%-8%964,1143.7
Jul 31, 20263.88M4.81%+4%520,0667.5
Jul 15, 20263.72M4.61%+4%566,4136.6
Jun 30, 20263.56M4.42%-9%851,4384.2
Jun 15, 20263.91M4.85%-1%552,8627.1
May 29, 20263.94M4.88%-6%798,5784.9
May 15, 20264.18M5.19%-17%1.07M3.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Protalix BioTherapeutics company events

Protalix BioTherapeutics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. Jun 25, 2026VoteReported shareholder vote results. Filing
  4. May 21, 2026AnnouncementShared information with investors. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Mar 18, 2026ResultsReleased financial results. Filing
  7. Mar 9, 2026AnnouncementProtalix BioTherapeutics, Inc., a Delaware corporation, issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that the European Commission (EC) has approved the 2 mg/kg every-4-weeks (E4W)… Filing
  8. Feb 11, 2026AnnouncementShared information with investors. Filing
  9. Jan 30, 2026AnnouncementProtalix BioTherapeutics, Inc., a Delaware corporation, issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European… Filing
  10. Jan 5, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Protalix BioTherapeutics financials

Famous investors that hold PLX

3 of the 50 well-known investors we track reported holding PLX in their latest 13F filing. The largest position is Jim Simons's, worth $2.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026988,100$2.7M0.0%-10%
Ken Griffin · Citadel AdvisorsQ3 2026281,229$776K0.0%-16%
Steve Cohen · Point72 Asset ManagementQ3 202613,027$36K0.0%-49%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PLX in the last 120 days.

FiledHolderFormStake
Oct 15, 2026HOLD Alapkezelo Zrt.13G5.2%
Oct 15, 2026HOLD Alapkezelo Zrt.13G5.2%

Questions about Protalix BioTherapeutics, Inc. (PLX) stock

Who owns the most PLX stock?

The largest reported owner of Protalix BioTherapeutics, Inc. (PLX) is BlackRock, Inc., with 5.0% of the company. In total, 102 funds and institutions reported holding PLX at the end of Q2 2026, together about 18% of the shares. See the largest owners.

Are PLX insiders buying or selling?

In the last 12 months, PLX insiders reported 1 open-market purchase worth $101K and 1 sale worth $314. The latest trade was on Dec 19, 2025. See every trade.

What is the short interest in PLX?

As of Oct 30, 2026, 3.48M PLX shares were sold short, 4.3% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 563,101 shares, buying them all back would take about 6.2 trading days (days to cover). See the history.

Which famous investors hold PLX?

3 of the 50 well-known investors we track reported PLX in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $2.7M. See all holders.

Executive pay

Protalix BioTherapeutics's chief executive was paid a total of $1.2M for the year ended Dec 31, 2025, down 24% from $1.5M the year before. In the last 12 months, Protalix BioTherapeutics's executives and directors bought $101K of stock on the open market and sold $314.

Chief executive, total pay$1.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$604KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.